Fat-Burning Still H...
Health Care: Drugs
Bionovo Inc. (BNVI: OTC)
$0.12 -0.02 | -11.54%
02/09/12 - 03:59 PM ET
1.10M / 551.70K
Vol / Avg. Vol:0.12 / 0.13
Open / Prev. Close:0.11 - 0.13
Today's Range:0.11 - 1.03
52 Wk Range:303.58%
Performance YTD:TheStreet Rating:
Portfolios with BNVI
- Portfolio NameUser Type
- Contributor16 Small-Cap Stocks in Dang...
- UserTom's Stock Picks
- UserEmerging biotech
- UserCougar Investment Playa Club
- Userswcarconsulting Portfolio 1
- UserASPSC
- Userteamjolly1 Portfolio 1
- Userlosers24
- Userbj's money
- UserSUPRATRADE-BIOTECH
Latest BNVI Headlines from TheStreet
- Biotech Stock Mailbag: Somaxon, Transcept 10.07.11 | 06:10 am
- 16 Small-Cap Stocks in Danger of Delisting 03.30.11 | 07:03 am
- Zale, Huntington Bancshares: Midday Volume Plays 04.21.10 | 10:04 am
- EnteroMedics, Bionovo: Early Volume Plays 01.14.10 | 09:01 am
- Trimeris, Bionovo: Early Volume Plays 12.29.09 | 09:12 am
- Friday's Small-Cap Winners & Losers 10.26.07 | 05:10 pm
- Street Smiles on Women's Health-Focused Biotech
06.27.07 | 12:06 pm - Stock Upgrades, Downgrades From TheStreet.com Ratings 06.01.07 | 12:06 pm
Press Releases for BNVI
- Bionovo Announces Findings Of Bezielle⢠Anticancer Properties And Active Principles - PR Newswire 02.07.12 | 08:02 am
- Bionovo To Voluntarily Delist From NASDAQ - PR Newswire 01.27.12 | 04:01 pm
- Robert Farrell Joins Bionovo's Board Of Directors - PR Newswire 01.05.12 | 08:01 am
- Bionovo Announces $5 Million Financing - PR Newswire 01.03.12 | 08:01 am
- Bionovo Announces The Publication Of Its Tissue Selective Estrogen Receptor Modulators For Postmenopausal Obesity - PR Newswire 12.08.11 | 08:12 am
- Bionovo Announces "First Patient, First Dose" In Menerba (MF101) Phase 3 Clinical Trial For Menopausal Hot Flashes - PR Newswire 11.16.11 | 12:11 pm
- Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial For Menopausal Hot Flashes - PR Newswire 10.26.11 | 04:10 pm
- Bionovo To Present Tissue Selective Estrogen Receptor Modulators For Obesity At The 22nd Annual Meeting Of The North American Menopause Society - PR Newswire 09.20.11 | 08:09 am
- Bionovo Announces An Additional 180 Day Period To Regain Compliance With Nasdaq's Bid Price Rule - PR Newswire 09.19.11 | 08:09 am
- Bionovo Announces Positive Results Of The Tolerability Trial Of Menerba (MF101) For Menopausal Hot Flashes - PR Newswire 08.30.11 | 08:08 am
Partner Headlines for BNVI
- Bionovo to Voluntarily Delist from NASDAQ - Benzinga 01.27.12 | 04:01 pm
- Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes - Benzinga 10.26.11 | 04:10 pm
- UPDATE 1-Bionovo gets FDA nod for lead drug development, shrs up - Reuters 11.10.10 | 10:11 am
- Investment Opportunities in Women's Health - Seeking Alpha 06.04.10 | 04:06 pm
